The drug Zyprexa was created in the hope that the debilitating broadside effects of handed-down antipsychotics would be abolished. whatsoever of these strict side effects enclosed extra pyramidal symptoms which influence, muscles and coordination, later dyskinea which causes random but fast body movements. In addition broadside effects such as neuroleptic malignant syndrome of high fevers, sweating and rough blood pressure were not uncommon. Even though these side effects were incapacitating and lasting, the need for reliable antipsychotic medications outweighed any latent harm they caused. It wasn’t until the 1970’s that the first ‘atypical’ antipsychotics were developed. These drugs assured relief from many neurological disorders without the so called ‘dangerous’ complication found in early drugs. To the relief of the many victims of neurological disorders, these drugs were found to be just as hard-hitting as previous medications, but reduced the occurrences of broadside effects. In 1996 Eli Lilly released Zyprexa and promised the unvarying reliable relief of schizophrenia and janus-faced disorders with equal fewer accompanying broadside effects. However, the dangers of traditional antipsychotics were still present and in addition, spic-and-span dangers of increases in diabetes, stroke and obesity came along with it. The nonindustrial side effects of Zyprexa became much and more calumniatory to the patient’s health.

NEW YORK (Reuters Health) - The prescription of antipsychotic medications for children and adolescents in the US increased nearly 6-fold between 1993 and 2002, according to survey results.